Current multiple sclerosis (MS) therapies are effective in reducing relapse rate, short-term measures of disability, and magnetic resonance imaging (MRI) measures of inflammation in relapsing remitting MS (RRMS), whereas in progressive/degenerative disease phases these medications are of little or no benefit. Therefore, the development of new therapies aimed at reversing neurodegeneration is of great interest. Remyelination, which is usually a spontaneous endogenous process, is achieved when myelin-producing oligodendrocytes are generated from oligodendrocyte precursor cells (OPCs). Even though these precursor cells are abundant in MS brains, their regeneration capacity is limited. Enhancing the generation of myelin-producing cells is therefore a major focus of MS research. Here we present an overview of the different advancements in the field of remyelination, including suitable animal models for testing remyelination therapies, approved medications with a proposed role in regeneration, myelin repair treatments under investigation in clinical trials, as well as future therapeutics aimed at facilitating myelin repair.
TrappBDNaveKA.Multiple sclerosis: An immune or neurodegenerative disorder?Annu Rev Neurosci2008; 31: 247–269.
3.
NaveKA.Myelination and the trophic support of long axons. Nat Rev Neurosci2010; 11: 275–283.
4.
KremerDKuryPDuttaR.Promoting remyelination in multiple sclerosis: Current drugs and future prospects. Mult Scler2015; 21: 541–549.
5.
XingYLRothPTStrattonJAet al. Adult neural precursor cells from the subventricular zone contribute significantly to oligodendrocyte regeneration and remyelination. J Neurosci2014; 34: 14128–14146.
FranklinRJffrench-ConstantCEdgarJMet al. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol2012; 8: 624–634.
8.
ChangATourtellotteWWRudickRet al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med2002; 346: 165–173.
9.
Nait-OumesmarBPicard-RieraNKerninonCet al. The role of SVZ-derived neural precursors in demyelinating diseases: From animal models to multiple sclerosis. J Neurol Sci2008; 265: 26–31.
10.
ChangANishiyamaAPetersonJet al. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci2000; 20: 6404–6412.
11.
PrineasJWConnellF.Remyelination in multiple sclerosis. Ann Neurol1979; 5: 22–31.
12.
KremerDAktasOHartungHPet al. The complex world of oligodendroglial differentiation inhibitors. Ann Neurol2011; 69: 602–618.
13.
ZamvilSSSteinmanL.The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol1990; 8: 579–621.
14.
TepavcevicVLazariniFAlfaro-CervelloCet al. Inflammation-induced subventricular zone dysfunction leads to olfactory deficits in a targeted mouse model of multiple sclerosis. J Clin Invest2011; 121: 4722–4734.
15.
LublinFD.Delayed, relapsing experimental allergic encephalomyelitis in mice. Role of adjuvants and pertussis vaccine. J Neurol Sci1982; 57: 105–110.
16.
BernardCCJohnsTGSlavinAet al. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J Mol Med1997; 75: 77–88.
17.
BlakemoreWF.Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol1972; 1: 413–426.
18.
KondoANakanoTSuzukiK.Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res1987; 425: 186–190.
19.
MatsushimaGKMorellP.The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol2001; 11: 107–116.
20.
RutherBJScheldMDreymuellerDet al. Combination of cuprizone and experimental autoimmune encephalomyelitis to study inflammatory brain lesion formation and progression. Glia2017; 65: 1900–1913.
21.
TsunodaIKuangLQFujinamiRS.Induction of autoreactive CD8+ cytotoxic T cells during Theiler’s murine encephalomyelitis virus infection: Implications for autoimmunity. J Virol2002; 76: 12834–12844.
22.
OlsonJKErcoliniAMMillerSD.A virus-induced molecular mimicry model of multiple sclerosis. Curr Top Microbiol Immunol2005; 296: 39–53.
23.
WoodruffRHFranklinRJ.Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: A comparative study. Glia1999; 25: 216–228.
24.
KeoughMBJensenSKYongVW.Experimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin. J Vis Exp2015; 97 (e52679): 1–8.
25.
BjelobabaIBegovic-KupresaninVPekovicSet al. Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis. J Neurosci Res2018; 96: 1021–1042.
26.
MeiFFancySPShenYAet al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med2014; 20: 954–960.
27.
GreenAJGelfandJMCreeBAet al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial. Lancet2017; 390: 2481–2489.
28.
JarskogLFLowyMTGroveRAet al. A phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res2015; 164: 136–142.
29.
GroveRAHarringtonCMMahlerAet al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res2014; 11: 47–58.
30.
SchwartzbachCJGroveRABrownRet al. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: A randomised, single-blind, phase II study. J Neurol2017; 264: 304–315.
MiSPepinskyRBCadavidD.Blocking LINGO-1 as a therapy to promote CNS repair: From concept to the clinic. CNS Drugs2013; 27: 493–503.
33.
CadavidDBalcerLGalettaSet al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): A randomised, placebo-controlled, phase 2 trial. Lancet Neurol2017; 16: 189–199.
34.
PerronHLangA.The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allerg Immu2010; 39: 51–61.
35.
KremerDSchichelTForsterMet al. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol2013; 74: 721–732.
36.
HauserSLBelachewSKapposL.Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med2017; 376: 1694.
37.
MontalbanXBelachewSWolinskyJS.Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med2017; 376: 1694.
38.
SorensenPSLyckeJEralinnaJPet al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial. Lancet Neurol2011; 10: 691–701.
39.
ChatawayJSchuererNAlsanousiAet al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet2014; 383: 2213–2221.
40.
SedelFBernardDMockDMet al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology2016; 110: 644–653.
41.
TourbahALebrun-FrenayCEdanGet al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler2016; 22: 1719–1731.
42.
BiXZhangYYanBet al. Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice. J Neurochem2012; 123: 14–20.
43.
LinkerRALeeDHRyanSet al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011; 134: 678–692.
44.
FujinoTKatoHYamashitaSet al. Effects of domperidone on serum prolactin levels in human beings. Endocrinol Jpn1980; 27: 521–525.
45.
GreggCShikarVLarsenPet al. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci2007; 27: 1812–1823.
46.
OkunoTNakatsujiYKumanogohA.The role of immune semaphorins in multiple sclerosis. FEBS Lett2011; 585: 3829–3835.
47.
KumanogohAMarukawaSSuzukiKet al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature2002; 419: 629–633.
48.
Moreau-FauvarqueCKumanogohACamandEet al. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci2003; 23: 9229–9239.
49.
GiraudonPVincentPVuaillatCet al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol2004; 172: 1246–1255.
50.
OkunoTNakatsujiYMoriyaMet al. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol2010; 184: 1499–1506.
ChandraratnaRANoelleRJNowakEC.Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis. Am J Transl Res2016; 8: 1016–1026.
53.
NowakEChandraratnaRNoelleR.IRX4204: A highly selective RXR agonist modulates adaptive Treg differentiation independent of RAR, and effectively inhibits central nervous system inflammation. Neurology2014; (Suppl 10): S14.005–6.
54.
MeiFMayoralSRNobutaHet al. Identification of the kappa-opioid receptor as a therapeutic target for oligodendrocyte remyelination. J Neurosci2016; 36: 7925–7935.
55.
MatloubianMLoCGCinamonGet al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature2004; 427: 355–360.
56.
JungCGKimHJMironVEet al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia2007; 55: 1656–1667.
57.
MironVELudwinSKDarlingtonPJet al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol2010; 176: 2682–2694.
KapposLBar-OrACreeBACet al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet2018; 391: 1263–1273.
60.
JurynczykMJurewiczABieleckiBet al. Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol2005; 170: 3–10.
61.
FancySPKotterMRHarringtonEPet al. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp Neurol2010; 225: 18–23.
62.
FancySPChanJRBaranziniSEet al. Myelin regeneration: A recapitulation of development?Annu Rev Neurosci2011; 34: 21–43.
63.
RossoSBSussmanDWynshaw-BorisAet al. Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci2005; 8: 34–42.
64.
SatoAKhadkaDKLiuWet al. Profilin is an effector for Daam1 in non-canonical Wnt signaling and is required for vertebrate gastrulation. Development2006; 133: 4219–4231.
65.
YingYTaoQ.Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics2009; 4: 307–312.
66.
WarnkeCStuveOKieseierBC.Teriflunomide for the treatment of multiple sclerosis. Clin Neurol Neurosurg2013; 115(Suppl. 1): S90–S94.
ConfavreuxCO’ConnorPComiGet al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13: 247–256.
69.
O’ConnorPComiGFreedmanMSet al. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology2016; 86: 920–930.
